الفهرس | Only 14 pages are availabe for public view |
Abstract Introduction Psoriasis is a chronic immune mediated ,genetically predisposed skin disease characterized by hyper-proliferation, and aberrant differentiation of keratinocytes affecting skin, nails, mucous membrane and joints. Genetical, immunological and environmental factors are thought to play a role in the etiology of psoriasis. The squamous cell carcinoma antigen (SCCA) belongs to the ovalbumin–serpin family and has been widely used as a tumor marker, particularly for squamous cell carcinoma. The functional role of SCCA in psoriasis plaques is unclear. SCCA might inhibit cellular apoptosis, which possibly leads to hyper proliferation of keratinocytes in psoriasis. SCCA2 transfection to human epidermal keratinocytes increase secretion of IL-6 (a key mediator of IL-23/Th17-driven cutaneous inflammation) and IL-1a, an alarmin, which stimulates the recruitment of inflammatory cells. The aim of work : The aim of this study was to assess serum level of SCCA2 in patients with psoriasis vulgaris and assess its relation with disease severity measured by PASI. Research Plan : This is a case-control study of 40 patients with psoriasis vulgaris (19 male &21 female with age median36 and range (2-73) years) and 40 matched healthy control group. The study was conducted in the period from July 2017 to January 2018.we excluded patients with malignancy, psoriatic arthritis and patients on treatment. Three ml of venous blood was collected from all patients with psoriasis vulgaris & healthy control group, serum was taken and stored frozen at -20oC until assay of SCCA2 using ELISA. Conclusion : from this study, it could be concluded that : 1- Serum levels of SCCA2 were elevated in patients with psoriasis vulgaris and were correlated with disease severity. 2- Serum levels of SCCA2 could be a promising biomarker in the diagnosis of psoriasis vulgaris and also could be used as a prognostic marker of disease severity. |